The channel blocker verapamil eliminates or reduces EADs, abolishes PVCs and suppresses TdP in congenital LQTS type 1 (LQT1) or type 2 (LQT2) caused by mutations in KCNQ1 or KCNH2 encoding KV7.1 or KV11.1 subunit responsible for the slowly or rapidly activating delayed rectifier potassium currents (IKs or IKr) respectively (8, 9) and in experimental models of LQT1 and 2 (10, 11) as well as type 3 (LQT3) (12) caused by mutations in SCN5A encoding sodium channel subunit NaV1.5. The gene discussed is SCN5A; the disease is long QT syndrome 1.